Megan Browdie

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised Alexandr Wang, Scale AI’s founder, in connection with Scale AI’s significant new investment from Meta Platforms that values the startup at more than $29 billion.

Cooley advised Philochem AG, a wholly owned subsidiary of the Philogen Group (Milan Stock Exchange: PHIL), on its definitive license agreement with RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), granting RayzeBio exclusive worldwide rights to develop, manufacture and commercialize OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer.

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.